

- Tamm R, Mägi R, Tremmel R, Winter S, Mihailov E, Smid A, Möricke A, Klein K, Schrappe M, Stanulla M, Houlston R, Weinshilboum R, Mlinarič Raščan I, Metspalu A, Milani L, Schwab M, Schaeffeler E. Polymorphic variation in TPMT is the principal determinant of TPMT phenotype: a meta-analysis of three genome-wide association studies. *Clin Pharmacol Ther.* doi: 10.1002/cpt.540 (2016).
- Vijayakrishnan J, Kumar R, Henrion MY, Moorman AV, Rachakonda PS, Hosen I, da Silva Filho MI, Holroyd A, Dobbins SE, Koehler R, Thomsen H, Irving JA, Allan JM, Lightfoot T, Roman E, Kinsey SE, Sheridan E, Thompson PD, Hoffmann P, Nöthen MM, Heilmann-Heimbach S, Karl-Heinz J, Greaves M, Harrison CJ, Bartram CR, Schrappe M, Stanulla M, Hemminki K, Houlston RS. A genome-wide association study identifies risk loci for childhood acute lymphoblastic leukemia at 10q26.13 and 12q23.1. *Leukemia.* doi: 10.1038/leu.2016.271 (2016).
- Palmi C, Savino AM, Silvestri D, Bronzini I, Cario G, Paganin M, Buldini B, Galbiati M, Muckenthaler MU, Bugarin C, Mina PD, Nagel S, Barisone E, Casale F, Locatelli F, Nigro LL, Micalizzi C, Parasole R, Pession A, Putti MC, Santoro N, Testi AM, Ziino O, Kulozik AE, Zimmermann M, Schrappe M, Villa A, Gaipa G, Basso G, Biondi A, Valsecchi MG, Stanulla M, Conter V, Kronnie GT, Cazzaniga G. CRLF2 over-expression is a poor prognostic marker in children with high risk T-cell acute lymphoblastic leukemia. *Oncotarget.* doi: 10.18632/oncotarget.10610 (2016).
- Schmiegelow K, Attarbaschi A, Barzilai S, Escherich G, Frandsen TL, Halsey C, Hough R, Jeha S, Kato M, Liang DC, Mikkelsen TS, Möricke A, Niinimäki R, Piette C, Putti MC, Raetz E, Silverman LB, Skinner R, Tuckuviene R, van der Sluis I, Zapotocka E; Ponte di Legno toxicity working group. Consensus definitions of 14 severe acute toxic effects for childhood lymphoblastic leukaemia treatment: a Delphi consensus. *Lancet Oncol* **17(6)**, e231-239 (2016).
- Boer JM, van der Veer A, Rizopoulos D, Fiocco M, Sonneveld E, de Groot-Kruseman HA, Kuiper RP, Hoogerbrugge P, Horstmann M, Zaliouva M, Palmi C, Trka J, Fronkova E, Emerenciano M, do Socorro Pombo-de-Oliveira M, Mlynarski W, Szczepanski T, Nebral K, Attarbaschi A, Venn N, Sutton R, Schwab CJ, Enshaei A, Vora A, Stanulla M, Schrappe M, Cazzaniga G, Conter V, Zimmermann M, Moorman AV, Pieters R, den Boer ML. Prognostic value of rare IKZF1 deletion in childhood B-cell precursor acute lymphoblastic leukemia: an international collaborative study. *Leukemia* **30(1)**, 32-38 (2016).
- Schütte P, Möricke A, Zimmermann M, Bleckmann K, Reismüller B, Attarbaschi A, Mann G, Bodmer N, Niggli F, Schrappe M, Stanulla M, Kratz CP. Preexisting conditions in pediatric ALL patients: Spectrum, frequency and clinical impact. *Eur J Med Genet* **59(3)**, 143-151 (2016).
- McComb S, Aguadé-Gorgorió J, Harder L, Marovca B, Cario G, Eckert C, Schrappe M, Stanulla M, von Stackelberg A, Bourquin JP, Bornhauser BC. Activation of concurrent apoptosis and necroptosis by SMAC mimetics for the treatment of refractory and relapsed ALL. *Sci Transl Med* **8(339)**, 339ra70 (2016).
- Tiphaine Ade B, Hjalgrim LL, Nersting J, Breitzkreutz J, Nelken B, Schrappe M, Stanulla M, Thomas C, Bertrand Y, Leverger G, Baruchel A, Schmiegelow K,

Jacqz-Aigrain E. Evaluation of a pediatric liquid formulation to improve 6-mercaptopurine therapy in children. *Eur J Pharm Sci* **83**, 1-7 (2016).

- Vora A, Andreano A, Pui CH, Hunger SP, Schrappe M, Moericke A, Biondi A, Escherich G, Silverman LB, Goulden N, Taskinen M, Pieters R, Horibe K, Devidas M, Locatelli F, Valsecchi MG. Influence of Cranial Radiotherapy on Outcome in Children With Acute Lymphoblastic Leukemia Treated With Contemporary Therapy. *J Clin Oncol* **34(9)**, 919-926 (2016).
- Bleckmann K, Schrappe M. Advances in therapy for Philadelphia-positive acute lymphoblastic leukaemia of childhood and adolescence. *Br J Haematol* **172(6)**, 855-869 (2016).
- Preuner S, Peters C, Pötschger U, Daxberger H, Fritsch G, Geyeregger R, Schrauder A, von Stackelberg A, Schrappe M, Bader P, Ebell W, Eckert C, Lang P, Sykora KW, Schrum J, Kremens B, Ehlert K, Albert MH, Meisel R, Lawitschka A, Mann G, Panzer-Grümayer R, Gungör T, Holter W, Strahm B, Gruhn B, Schulz A, Woessmann W, Lion T. Risk assessment of relapse by lineage-specific monitoring of chimerism in children undergoing allogeneic stem cell transplantation for acute lymphoblastic leukemia. *Haematologica* **101(6)**, 741-746 (2016).
- Möricke A, Zimmermann M, Valsecchi MG, Stanulla M, Biondi A, Mann G, Locatelli F, Cazzaniga G, Niggli F, Aricò M, Bartram CR, Attarbaschi A, Silvestri D, Beier R, Basso G, Ratei R, Kulozik AE, Lo Nigro L, Kremens B, Greiner J, Parasole R, Harbott J, Caruso R, von Stackelberg A, Barisone E, Rössig C, Conter V, Schrappe M. Dexamethasone vs prednisone in induction treatment of pediatric ALL: results of the randomized trial AIEOP-BFM ALL 2000. *Blood* **127(17)**, 2101-2112 (2016).
- Zuna J, Moericke A, Arens M, Koehler R, Panzer-Grümayer R, Bartram CR, Fischer S, Fronkova E, Zaliova M, Schrauder A, Stanulla M, Zimmermann M, Trka J, Sary J, Attarbaschi A, Mann G, Schrappe M, Cario G. Implications of delayed bone marrow aspirations at the end of treatment induction for risk stratification and outcome in children with acute lymphoblastic leukaemia. *Br J Haematol* **173(5)**, 742-748 (2016).
- Peters C, Schrappe M, von Stackelberg A, Schrauder A, Bader P, Ebell W, Lang P, Sykora KW, Schrum J, Kremens B, Ehlert K, Albert MH, Meisel R, Matthes-Martin S, Gungor T, Holter W, Strahm B, Gruhn B, Schulz A, Woessmann W, Poetschger U, Zimmermann M, Klingebiel T. Stem-cell transplantation in children with acute lymphoblastic leukemia: A prospective international multicenter trial comparing sibling donors with matched unrelated donors-The ALL-SCT-BFM-2003 trial. *J Clin Oncol* **33(11)**, 1265-1274 (2015).
- Alten J, Klapper W, Leuschner I, Eckert C, Beier R, Vallo E, Krause M, Claviez A, Vieth S, Bleckmann K, Möricke A, Schrappe M, Cario G. Secondary histiocytic sarcoma may cause apparent persistence or recurrence of minimal residual disease in childhood acute lymphoblastic leukemia. *Pediatr Blood Cancer* **62(9)**, 1656-1660 (2015).
- Bartram T, Burkhardt B, Wössmann W, Seidemann K, Zimmermann M, Cario G, Lisfeld J, Ellinghaus E, Franke A, Houlston RS, Schrappe M, Reiter A, Stanulla M. Childhood acute lymphoblastic leukemia-associated risk-loci IKZF1, ARID5B and CEBPE and risk of pediatric non-Hodgkin lymphoma: a

report from the Berlin-Frankfurt-Münster Study Group. *Leuk Lymphoma* **56(3)**, 814–816 (2015).

- Eckert C, Hagedorn N, Sramkova L, Mann G, Panzer-Grümayer R, Peters C, Bourquin JP, Klingebiel T, Borkhardt A, Cario G, Alten J, Escherich G, Astrahantseff K, Seeger K, Henze G, von Stackelberg A. Monitoring minimal residual disease in children with high-risk relapses of acute lymphoblastic leukemia: prognostic relevance of early and late assessment. *Leukemia* **29(8)**, 1648–1655 (2015).
- Alexander S, Pole JD, Gibson P, Lee M, Hesser T, Chi SN, Dvorak CC, Fisher B, Hasle H, Kanerva J, Möricke A, Phillips B, Raetz E, Rodriguez-Galindo C, Samarasinghe S, Schmiegelow K, Tissing W, Lehrnbecher T, Sung L; International Pediatric Oncology Mortality Classification Group. Classification of treatment-related mortality in children with cancer: a systematic assessment. *Lancet Oncol* **16(16)**, 604-610 (2015).
- Pritchard-Jones K, Bergeron C, de Camargo B, van den Heuvel-Eibrink MM, Acha T, Godzinski J, Oldenburger F, Boccon-Gibod L, Leuschner I, Vujanic G, Sandstedt B, de Kraker J, van Tinteren H, Graf N; SIOP Renal Tumours Study Group. Omission of doxorubicin from the treatment of stage II-III, intermediate-risk Wilms' tumour (SIOP WT 2001): an open-label, non-inferiority, randomised controlled trial. *Lancet* **386(9999)**, 1156-1164 (2015).
- Junk S, Cario G, Wittner N, Stanulla M, Scherer R, Schlegelberger B, Schrappe M, von Neuhoff N, Lauten M. Bortezomib Treatment can Overcome Glucocorticoid Resistance in Childhood B-cell Precursor Acute Lymphoblastic Leukemia Cell Lines. *Klin Padiatr* **227(3)**, 123-130 (2015).
- Pui CH, Yang JJ, Hunger SP, Pieters R, Schrappe M, Biondi A, Vora A, Baruchel A, Silverman LB, Schmiegelow K, Escherich G, Horibe K, Benoit YC, Izraeli S, Yeoh AE, Liang DC, Downing JR, Evans WE, Relling MV, Mullighan CG. Childhood Acute Lymphoblastic Leukemia: Progress Through Collaboration. *J Clin Oncol* **33(27)**, 2938-2948 (2015).
- Baader P, Kreyenberg H, von Stackelberg, Eckert C, Salzmann-Manrique E, Meisel R, Poetschger U, Stachel D, Schrappe M, Alten J, Schrauder A, Schulz Á, Lang P, Müller I, Albert MH, Willaasch AM, Klingbiel TE, Peters C. Monitoring of minimal residual disease after allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia allows for the identification of impending relapse: results of the ALL-BFM-SCT 2003 trial. *J Clin Oncol* **33(11)**, 4631-4631 (2015).
- Ammann RA, Laws HJ, Schrey D, Ehlert K, Moser O, Dilloo D, Bode U, Wawer A, Schrauder A, Cario G, Laengler A, Graf N, Furtwängler R, Simon A. Bloodstream infection in paediatric cancer centres - leukaemia and relapsed malignancies are independent risk factors. *Eur J Cancer* **174(5)**, 675-686 (2015).
- Vassal G, Rousseau R, Blanc P, Moreno L, Bode G, Schwoch S, Schrappe M, Skolnik J, Bergman L, Bradley-Garelik MB, Saha V, Pearson A, Zwierzina H. Creating a unique, multi-stakeholder Paediatric Oncology Platform to improve drug development for children and adolescents with cancer. *Eur J Cancer* **51(2)**, 218-224 (2015).

- Schrappe M. Detection and management of minimal residual disease in acute lymphoblastic leukemia. *Hematology Am Soc Hematol Educ Program* **2014(1)**, 244-9 (2014).
- Vassal G, Fitzgerald E, Schrappe M, Arnold F, Kowalczyk J, Walker D, Hjorth L, Riccardi R, Kienesberger A, Jones KP, Valsecchi MG, Janic D, Hasle H, Kearns P, Petrarulo G, Florindi F, Essiaf S, Ladenstein R. Challenges for children and adolescents with cancer in Europe: the SIOP-Europe agenda. *Lancet Oncol* **61(9)**, 1551-1557 (2014).
- Millot F, Claviez A, Leverger G, Corbaciglu S, Groll AH, Suttorp M. Imatinib cessation in children and adolescents with chronic myeloid leukemia in chronic phase. *Pediatr Blood Cancer* **61(2)**, 355-357 (2014).
- Lauten M, Vieth S, Hart C, Wössmann W, Tröger B, Härtel C, Bethge M, Schrauder A, Cario G. Cardiac anaplastic large cell lymphoma in an 8-year old boy. *Leuk Res Rep* **3(2)**, 36-37 (2014).
- Attarbaschi A, Panzer-Grümayer R, Mann G, Möricke A, König M, Mecklenbräuker A, Teigler-Schlegel A, Bradtke J, Harbott J, Göhring G, Stanulla M, Schrappe M, Zimmermann M, Haas OA; Austrian and German ALL-BFM (Berlin-Frankfurt-Münster) Study Group. Minimal residual disease-based treatment is adequate for relapse-prone childhood acute lymphoblastic leukemia with an intrachromosomal amplification of chromosome 21: the experience of the ALL-BFM 2000 trial. *Klin Padiatr* **226(6-7)**, 338-343 (2014).
- Stary J, Zimmermann M, Campbell M, Castillo L, Dibar E, Donska S, Gonzalez A, Izraeli S, Janic D, Jazbec J, Konja J, Kaiserova E, Kowalczyk J, Kovacs G, Li CK, Magyarosy E, Popa A, Stark B, Jabali Y, Trka J, Hrusak O, Riehm H, Masera G, Schrappe M. Intensive chemotherapy for childhood acute lymphoblastic leukemia: results of the randomized intercontinental trial ALL IC-BFM 2002. *J Clin Oncol* **32(3)**, 174-184 (2014).
- Lüders H, Rühl U, Marciniak H, Haerting J, Claviez A, Mann G, Schellong G, Wickmann L, Dörffel W. The impact of central review and central therapy planning on the treatment of children and adolescents with Hodgkin lymphoma. *Eur J Cancer* **50(2)**, 425-433 (2014).
- Buitenkamp TD, Izraeli S, Zimmermann M, Forestier E, Heerema NA, van den Heuvel-Eibrink MM, Pieters R, Korbijn CM, Silverman LB, Schmiegelow K, Liang DC, Horibe K, Arico M, Biondi A, Basso G, Rabin KR, Schrappe M, Cario G, Mann G, Morak M, Panzer-Grümayer R, Mondelaers V, Lammens T, Cavé H, Stark B, Ganmore I, Moorman AV, Vora A, Hunger SP, Pui CH, Mullighan CG, Manabe A, Escherich G, Kowalczyk JR, Whitlock JA, Zwaan CM. Acute lymphoblastic leukemia in children with Down syndrome: a retrospective analysis from the Ponte di Legno study group. *Blood* **123(1)**, 70-77 (2014).
- Geiger F, Wolfgram L. Overshadowing as prevention of anticipatory nausea and vomiting in pediatric cancer patients: study protocol for a randomized controlled trial. *Trials* **14**, 103-104 (2013).
- Volks N, Oschlies I, Cario G, Weichenthal M, Fölster-Holst R. Primary cutaneous CD4+ small to medium-size pleomorphic T-cell lymphoma in a 12-year-old girl. *Pediatr Dermatol* **30(5)**, 595-599 (2013).

- Rossig C, Juergens H, Schrappe M, Moericke A, Henze G, von Stackelberg A, Reinhardt D, Burkhardt B, Woessmann W, Zimmermann M, Gadner H, Mann G, Schellong G, Mauz-Koerholz C, Dirksen U, Bielack S, Berthold F, Graf N, Rutkowski S, Calaminus G, Kaatsch P, Creutzig U. Effective childhood cancer treatment: the impact of large scale clinical trials in Germany and Austria. *Pediatr Blood Cancer* **60(10)**, 1574-1581 (2013).
- Hunger SP, Baruchel A, Biondi A, Evans WE, Jeha S, Loh M, Moericke A, Pieters R, Relling MV, Schmiegelow K, Schrappe M, Silverman LB, Stanulla M, Valsecchi MG, Vora A, Pui CH. The thirteenth international childhood acute lymphoblastic leukemia workshop report: La Jolla, CA, USA, December 7-9, 2011. *Pediatr Blood Cancer* **60(2)**, 344-348 (2013).
- Schrappe M, Möricke A, Reiter A, Henze G, Welte K, Gadner H, Ludwig WD, Ritter J, Harbott J, Mann G, Klingebiel T, Gruhn B, Niemeyer C, Kremens B, Niggli F, Debatin KM, Ratei R, Stanulla M, Beier R, Cario G, Schrauder A, Zimmermann M. Key treatment questions in childhood acute lymphoblastic leukemia: results in 5 consecutive trials performed by the ALL-BFM study group from 1981 to 2000. *Klin Padiatr* **225** Suppl 1, 62-71 (2013).
- Ratei R, Schabath R, Karawajew L, Zimmermann M, Möricke A, Schrappe M, Ludwig WD. Lineage classification of childhood acute lymphoblastic leukemia according to the EGIL recommendations: results of the ALL-BFM 2000 trial. *Klin Padiatr* **225** Suppl 1, 34-39 (2013).
- Möricke A, Lauten M, Beier R, Odenwald E, Stanulla M, Zimmermann M, Attarbaschi A, Niggli F, Schrappe M. Prediction of outcome by early response in childhood acute lymphoblastic leukemia. *Klin Padiatr* **225** Suppl 1, 50-56 (2013).
- Schmiegelow K, Levinsen MF, Attarbaschi A, Baruchel A, Devidas M, Escherich G, Gibson B, Heydrich C, Horibe K, Ishida Y, Liang DC, Locatelli F, Michel G, Pieters R, Piette C, Pui CH, Raimondi S, Silverman L, Stanulla M, Stark B, Winick N, Valsecchi MG. Second malignant neoplasms after treatment of childhood acute lymphoblastic leukemia. *J Clin Oncol* **31(19)**, 2469-2476 (2013).
- Eckert C, Henze G, Seeger K, Hagedorn N, Mann G, Panzer-Grümayer R, Peters C, Klingebiel T, Borkhardt A, Schrappe M, Schrauder A, Escherich G, Sramkova L, Niggli F, Hitzler J, von Stackelberg A. Use of allogeneic hematopoietic stem-cell transplantation based on minimal residual disease response improves outcomes for children with relapsed acute lymphoblastic leukemia in the intermediate-risk group. *J Clin Oncol* **31(21)**, 2736-2742 (2013).
- Dörffel W, Rühl U, Lüders H, Claviez A, Albrecht M, Bökkerink J, Holte H, Karlen J, Mann G, Marciniak H, Niggli F, Schmiegelow K, Schwarze EW, Pötter R, Wickmann L, Schellong G. Treatment of children and adolescents with Hodgkin lymphoma without radiotherapy for patients in complete remission after chemotherapy: final results of the multinational trial GPOH-HD95. *J Clin Oncol* **31(12)**, 1562-1568 (2013).
- Rizzari C, Conter V, Starý J, Colombini A, Moericke A, Schrappe M. Optimizing asparaginase therapy for acute lymphoblastic leukemia. *Curr Opin Oncol*. **Suppl 1**, 1-9 (2013).

- Meyr F, Escherich G, Mann G, Klingebiel T, Kulozik A, Rossig C, Schrappe M, Henze G, von Stackelberg A, Hitzler J. Outcomes of treatment for relapsed acute lymphoblastic leukaemia in children with Down syndrome. *Br J Haematol.* **162(1)**, 98-106 (2013).
- Meisel R, Klingebiel T, Dilloo D; German/Austrian Pediatric Registry for Stem Cell Transplantation. Peripheral blood stem cells versus bone marrow in pediatric unrelated donor stem cell transplantation. *Blood* **121(5)**, 863-865 (2013).
- Creutzig U, Zimmermann M, Bourquin JP, Dworzak MN, Fleischhack G, Graf N, Klingebiel T, Kremens B, Lehrnbecher T, von Neuhoff C, Ritter J, Sander A, Schrauder A, von Stackelberg A, Starý J, Reinhardt D. Randomized trial comparing liposomal daunorubicin with idarubicin as induction for pediatric acute myeloid leukemia: results from Study AML-BFM 2004. *Blood* **122(1)**, 37-43 (2013).
- Czajczynska A, Günther A, Repp R, Humpe A, Schub N, Raff T, Nickelsen M, Schrauder A, Schrappe M, Kneba M, Gramatzki M. Allogeneic stem cell transplantation with BEAM and alemtuzumab conditioning immediately after remission induction has curative potential in advanced T-cell non-Hodgkin's lymphoma. *Biol Blood Marrow Transplant.* **19(11)**, 1632-1637 (2013).
- Schrappe M, Hunger SP, Pui CH, Saha V, Gaynon PS, Baruchel A, Conter V, Otten J, Ohara A, Versluys AB, Escherich G, Heyman M, Silverman LB, Horibe K, Mann G, Camitta BM, Harbott J, Riehm H, Richards S, Devidas M, Zimmermann M. Outcomes after induction failure in childhood acute lymphoblastic leukemia. *N Engl J* **366(15)**, 1371-1381 (2012).
- Biondi A, Schrappe M, De Lorenzo P, Castor A, Lucchini G, Gandemer V, Pieters R, Stary J, Escherich G, Campbell M, Li CK, Vora A, Aricò M, Röttgers S, Saha V, Valsecchi MG. Imatinib after induction for treatment of children and adolescents with Philadelphia-chromosome-positive acute lymphoblastic leukaemia (EsPhALL): a randomised, open-label, intergroup study. *Lancet Oncol.* **13(9)**, 936-945 (2012).
- Zeidler L, Zimmermann M, Möricke A, Meissner B, Bartels D, Tschan C, Schrauder A, Cario G, Goudeva L, Jäger S, Ratei R, Ludwig WD, Teigler-Schlegel A, Skokowa J, Koehler R, Bartram CR, Riehm H, Schrappe M, Welte K, Stanulla M. Low platelet counts after induction therapy for childhood acute lymphoblastic leukemia are strongly associated with poor early response to treatment as measured by minimal residual disease and are prognostic for treatment outcome. *Haematologica* **97(3)**, 402-409 (2012).
- Lauten M, Möricke A, Beier R, Zimmermann M, Stanulla M, Meissner B, Odenwald E, Attarbaschi A, Niemeyer C, Niggli F, Riehm H, Schrappe M. Prediction of outcome by early bone marrow response in childhood acute lymphoblastic leukemia treated in the ALL-BFM 95 trial: differential effects in precursor B-cell and T-cell leukemia. *Haematologica* **97(7)**, 1048-1056 (2012).
- Eckert C, von Stackelberg A, Seeger K, Groeneveld TW, Peters C, Klingebiel T, Borkhardt A, Schrappe M, Escherich G, Henze G. Minimal residual disease after induction is the strongest predictor of prognosis in intermediate risk relapsed acute lymphoblastic leukaemia - Long-term results of trial ALL-REZ BFM P95/96. *Eur J Cancer* **49(6)**, 895-897 (2013).

- Beier R, Albert MH, Bader P, Borkhardt A, Creutzig U, Eyrich M, Ehlert K, Gruhn B, Greil J, Handgretinger R, Holter W, Klingebiel T, Kremens B, Lang P, Mauz-Körholz C, Meisel R, Müller I, Peters C, Reinhardt D, Sedlacek P, Schulz A, Schuster FR, Schrauder A, Strahm B, Sykora KW, Wössmann W, Zimmermann M, Sauer MG. Allo-SCT using BU, CY and melphalan for children with AML in second CR. *Bone Marrow Transpl* **48(5)**, 651-656 (2013).
- Bartram CR, Schrauder A, Köhler R, Schrappe M. Acute lymphoblastic leukemia in children: treatment planning via minimal residual disease assessment. *Dtsch Arztebl Int.* **109(40)**, 652-658 (2012).
- Locatelli F, Schrappe M, Bernardo ME, Rutella S. How I treat relapsed childhood acute lymphoblastic leukemia. *Blood* **158**, 2807-2816 (2012).
- Creutzig U, Zimmermann M, Bourquin JP, Dworzak MN, Fleischhack G, von Neuhoff C, Sander A, Schrauder A, von Stackelberg A, Ritter J, Starý J, Reinhardt D. CNS irradiation in pediatric acute myeloid leukemia: equal results by 12 or 18 Gy in studies AML-BFM98 and 2004. *Pediatr Blood Cancer* **57(6)**, 986-992 (2011).
- Burkhardt B, Oschlies I, Klapper W, Zimmermann M, Woessmann W, Meinhardt A, Landmann E, Attarbaschi A, Niggli F, Schrappe M, Reiter A Non-Hodgkin's lymphoma in adolescents: experiences in 378 adolescent NHL patients treated according to pediatric NHL-BFM protocols. *Leukemia* **25(1)**, 153-160 (2011).
- Zeidler L, Zimmermann M, Möricke A, Meissner B, Bartels D, Tschan C, Schrauder A, Cario G, Goudeva L, Jäger S, Ratei R, Ludwig WD, Teigler-Schlegel A, Skokowa J, Koehler R, Bartram CR, Riehm H, Schrappe M, Welte K, Stanulla M. Low platelet counts after induction therapy for childhood acute lymphoblastic leukemia are strongly associated with poor early response to treatment as measured by minimal residual disease and are prognostic for treatment outcome. *Haematologica* **97(3)**, 402-409 (2011).
- von Stackelberg A, Völzke E, Köhl JS, Seeger K, Schrauder A, Escherich G, Henze G, Tallen G; ALL-REZ BFM Study Group. Outcome of children and adolescents with relapsed acute lymphoblastic leukaemia and non-response to salvage protocol therapy: a retrospective analysis of the ALL-REZ BFM Study Group. *Eur J Cancer* **47(1)**, 90-97 (2011).
- Pieters R, Hunger SP, Boos J, Rizzari C, Silverman L, Baruchel A, Goekbuget N, Schrappe M, Pui CH. L-asparaginase treatment in acute lymphoblastic leukemia: a focus on Erwinia asparaginase. *Cancer* **117(2)**, 238-249 (2011).
- Schub N, Günther A, Schrauder A, Claviez A, Ehlert C, Gramatzki M, Repp R Therapy of steroid-refractory acute GVHD with CD52 antibody alemtuzumab is effective. *Bone Marrow Transpl* **46(1)**, 143-147 (2011)
- Simon T, Hero B, Faldum A, Handgretinger R, Schrappe M, Klingebiel T, Berthold F. Long term outcome of high-risk neuroblastoma patients after immunotherapy with antibody ch14.18 or oral metronomic chemotherapy. *BMC Cancer* **11**, 21-21 (2011).
- Willer A, Gerss J, König T, Franke D, Kühnel HJ, Henze G, von Stackelberg A, Möricke A, Schrappe M, Boos J, Lanvers-Kaminsky C. Anti-Escherichia coli asparaginase antibody levels determine the activity of second-line

treatment with pegylated E coli asparaginase: a retrospective analysis within the ALL-BFM trials. *Blood* **118(22)**, 5774-5782 (2011).

- Steinbach, D., Wilhelm, B., Kiermaier, H.R., Creutzig, U., Schrappe, M., Zimmermann, M., Debatin, K.M., Gruhn, B., von Stackelberg, A., Jurgens, H., Strahm, B., Reinhardt, D. & Moricke, A. Long term survival in children with acute leukaemia and complications requiring mechanical ventilation. *Arch Dis Child* (2011).
- Schrappe, M., Valsecchi, M.G., Bartram, C.R., Schrauder, A., Panzer-Grumayer, R., Moricke, A., Parasole, R., Zimmermann, M., Dworzak, M., Buldini, B., Reiter, A., Basso, G., Klingebiel, T., Messina, C., Ratei, R., Cazzaniga, G., Koehler, R., Locatelli, F., Schafer, B.W., Arico, M., Welte, K., van Dongen, J.J., Gadner, H., Biondi, A. & Conter, V. Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL: results of the AIEOP-BFM-ALL 2000 study. *Blood* **118**, 2077-2084 (2011).
- Eckert, C., Flohr, T., Koehler, R., Hagedorn, N., Moericke, A., Stanulla, M., Kirschner-Schwabe, R., Cario, G., Stackelberg, A., Bartram, C.R., Henze, G., Schrappe, M. & Schrauder, A. Very early/early relapses of acute lymphoblastic leukemia show unexpected changes of clonal markers and high heterogeneity in response to initial and relapse treatment. *Leukemia* **25**, 1305-1313 (2011).
- Bienemann, K., Burkhardt, B., Modlich, S., Meyer, U., Moricke, A., Mauz-Korholz, C., Escherich, G., Zimmermann, M., Korholz, D., Janka-Schaub, G., Schrappe, M., Reiter, A. & Borkhardt, A. Promising therapy results for lymphoid malignancies in children with chromosomal breakage syndromes (Ataxia teleangiectasia or Nijmegen-breakage syndrome): a retrospective survey. *Br J Haematol* (2011).
- Schrappe M. Mitoxantrone in first-relapse paediatric ALL: the ALL R3 trial. *Lancet* **376(9757)**, 1968-1970 (2010).
- Steiner, M., Attarbaschi, A., Dworzak, M., Strobl, H., Pickl, W., Kornmuller, R., Haas, O., Gadner, H. & Mann, G. Cytochemically myeloperoxidase positive childhood acute leukemia with lymphoblastic morphology treated as lymphoblastic leukemia. *J Pediatr Hematol Oncol* **32**, e4-7 (2010).
- Pichler, H., Moricke, A., Mann, G., Teigler-Schlegel, A., Niggli, F., Nebral, K., Konig, M., Inthal, A., Krehan, D., Dworzak, M.N., Janousek, D., Harbott, J., Schrappe, M., Gadner, H., Strehl, S., Haas, O.A., Panzer-Grumayer, R. & Attarbaschi, A. Prognostic relevance of dic(9;20)(p11;q13) in childhood B-cell precursor acute lymphoblastic leukaemia treated with Berlin-Frankfurt-Munster (BFM) protocols containing an intensive induction and post-induction consolidation therapy. *Br J Haematol* **149**, 93-100 (2010).
- Krieger, D., Moericke, A., Oschlies, I., Zimmermann, M., Schrappe, M., Reiter, A. & Burkhardt, B. Frequency and clinical relevance of DNA microsatellite alterations of the CDKN2A/B, ATM and p53 gene loci: a comparison between pediatric precursor T-cell lymphoblastic lymphoma and T-cell lymphoblastic leukemia. *Haematologica* **95**, 158-162 (2010).
- Hempel, G., Muller, H.J., Lanvers-Kaminsky, C., Wurthwein, G., Hoppe, A. & Boos, J. A population pharmacokinetic model for pegylated-asparaginase in children. *Br J Haematol* **148**, 119-125 (2010).

- Cario, G., Zimmermann, M., Romey, R., Gesk, S., Vater, I., Harbott, J., Schrauder, A., Moericke, A., Izraeli, S., Akasaka, T., Dyer, M.J., Siebert, R., Schrappe, M. & Stanulla, M. Presence of the P2RY8-CRLF2 rearrangement is associated with a poor prognosis in non-high-risk precursor B-cell acute lymphoblastic leukemia in children treated according to the ALL-BFM 2000 protocol. *Blood* **115**, 5393-5397 (2010).
- Stanulla, M. & Schrauder, A. Bridging the gap between the north and south of the world: the case of treatment response in childhood acute lymphoblastic leukemia. *Haematologica* **94**, 748-752 (2009).
- Stanulla, M. & Schrappe, M. Treatment of childhood acute lymphoblastic leukemia. *Semin Hematol* **46**, 52-63 (2009).
- Stanulla, M., Schaeffeler, E., Moricke, A., Coulthard, S.A., Cario, G., Schrauder, A., Kaatsch, P., Dordelmann, M., Welte, K., Zimmermann, M., Reiter, A., Eichelbaum, M., Riehm, H., Schrappe, M. & Schwab, M. Thiopurine methyltransferase genetics is not a major risk factor for secondary malignant neoplasms after treatment of childhood acute lymphoblastic leukemia on Berlin-Frankfurt-Munster protocols. *Blood* **114**, 1314-1318 (2009).
- Prucker, C., Attarbaschi, A., Peters, C., Dworzak, M.N., Potschger, U., Urban, C., Fink, F.M., Meister, B., Schmitt, K., Haas, O.A., Gadner, H. & Mann, G. Induction death and treatment-related mortality in first remission of children with acute lymphoblastic leukemia: a population-based analysis of the Austrian Berlin-Frankfurt-Munster study group. *Leukemia* **23**, 1264-1269 (2009).
- Kidas, E., Moricke, A., Beier, R., Welte, K., Schrappe, M., Stanulla, M. & Grigull, L. Genetic polymorphisms of the lymphotoxin alpha gene are associated with increased risk for lethal infections during induction therapy for childhood acute leukemia: a case-control study. *Int J Hematol* **89**, 584-591 (2009).
- Teuffel, O., Stanulla, M., Cario, G., Ludwig, W.D., Rottgers, S., Schafer, B.W., Zimmermann, M., Schrappe, M. & Niggli, F.K. Anemia and survival in childhood acute lymphoblastic leukemia. *Haematologica* **93**, 1652-1657 (2008).
- Steiner, M., Attarbaschi, A., Haas, O.A., Kastner, U., Gadner, H. & Mann, G. Fresh frozen plasma contains free asparagine and may replace the plasma asparagine pool during L-asparaginase therapy. *Leukemia* **22**, 1290 (2008).
- Schrauder, A., von Stackelberg, A., Schrappe, M., Cornish, J. & Peters, C. Allogeneic hematopoietic SCT in children with ALL: current concepts of ongoing prospective SCT trials. *Bone Marrow Transplant* **41 Suppl 2**, S71-74 (2008).
- Schrappe, M. Risk-adapted stratification and treatment of childhood acute lymphoblastic leukaemia. *Radiat Prot Dosimetry* **132**, 130-133 (2008).
- Moricke, A., Reiter, A., Zimmermann, M., Gadner, H., Stanulla, M., Dordelmann, M., Loning, L., Beier, R., Ludwig, W.D., Ratei, R., Harbott, J., Boos, J., Mann, G., Niggli, F., Feldges, A., Henze, G., Welte, K., Beck, J.D., Klingebiel, T., Niemeyer, C., Zintl, F., Bode, U., Urban, C., Wehinger, H.,

Niethammer, D., Riehm, H. & Schrappe, M. Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95. *Blood* **111**, 4477-4489 (2008).

- Cario, G., Fetz, A., Bretscher, C., Moricke, A., Schrauder, A., Stanulla, M. & Schrappe, M. Initial leukemic gene expression profiles of patients with poor in vivo prednisone response are similar to those of blasts persisting under prednisone treatment in childhood acute lymphoblastic leukemia. *Ann Hematol* **87**, 709-716 (2008).
- Burkhardt, B., Moericke, A., Klapper, W., Greene, F., Salzburg, J., Damm-Welk, C., Zimmermann, M., Strauch, K., Ludwig, W.D., Schrappe, M. & Reiter, A. Pediatric precursor T lymphoblastic leukemia and lymphoblastic lymphoma: Differences in the common regions with loss of heterozygosity at chromosome 6q and their prognostic impact. *Leuk Lymphoma* **49**, 451-461 (2008).
- Attarbaschi, A., Mann, G., Panzer-Grumayer, R., Rottgers, S., Steiner, M., Konig, M., Csinady, E., Dworzak, M.N., Seidel, M., Janousek, D., Moricke, A., Reichelt, C., Harbott, J., Schrappe, M., Gadner, H. & Haas, O.A. Minimal residual disease values discriminate between low and high relapse risk in children with B-cell precursor acute lymphoblastic leukemia and an intrachromosomal amplification of chromosome 21: the Austrian and German acute lymphoblastic leukemia Berlin-Frankfurt-Munster (ALL-BFM) trials. *J Clin Oncol* **26**, 3046-3050 (2008).
- Steiner, M., Attarbaschi, A., Kastner, U., Dworzak, M., Haas, O.A., Gadner, H. & Mann, G. Distinct fluctuations of ammonia levels during asparaginase therapy for childhood acute leukemia. *Pediatr Blood Cancer* **49**, 640-642 (2007).
- Stanulla, M., Cario, G., Meissner, B., Schrauder, A., Moricke, A., Riehm, H. & Schrappe, M. Integrating molecular information into treatment of childhood acute lymphoblastic leukemia--a perspective from the BFM Study Group. *Blood Cells Mol Dis* **39**, 160-163 (2007).
- Schrauder, A., Henke-Gendo, C., Seidemann, K., Sasse, M., Cario, G., Moericke, A., Schrappe, M., Heim, A. & Wessel, A. Varicella vaccination in a child with acute lymphoblastic leukaemia. *Lancet* **369**, 1232 (2007).
- Pieters, R., Schrappe, M., De Lorenzo, P., Hann, I., De Rossi, G., Felice, M., Hovi, L., LeBlanc, T., Szczepanski, T., Ferster, A., Janka, G., Rubnitz, J., Silverman, L., Stary, J., Campbell, M., Li, C.K., Mann, G., Suppiah, R., Biondi, A., Vora, A. & Valsecchi, M.G. A treatment protocol for infants younger than 1 year with acute lymphoblastic leukaemia (Interfant-99): an observational study and a multicentre randomised trial. *Lancet* **370**, 240-250 (2007).
- Mann, G., Steiner, M. & Attarbaschi, A. Clinical significance of anti-asparaginase antibodies in childhood acute lymphoblastic leukemia. *Leuk Lymphoma* **48**, 849-850 (2007).
- Mann, G., Cazzaniga, G., van der Velden, V.H., Flohr, T., Csinady, E., Paganin, M., Schrauder, A., Dohnal, A.M., Schrappe, M., Biondi, A., Gadner, H., van Dongen, J.J. & Panzer-Grumayer, E.R. Acute lymphoblastic leukemia

with t(4;11) in children 1 year and older: The 'big sister' of the infant disease? *Leukemia* **21**, 642-646 (2007).

- Krappmann, P., Paulides, M., Stohr, W., Ittner, E., Plattig, B., Nickel, P., Lackner, H., Schrappe, M., Janka, G., Beck, J.D. & Langer, T. Almost normal cognitive function in patients during therapy for childhood acute lymphoblastic leukemia without cranial irradiation according to ALL-BFM 95 and COALL 06-97 protocols: results of an Austrian-German multicenter longitudinal study and implications for follow-up. *Pediatr Hematol Oncol* **24**, 101-109 (2007).
- Conter, V., Valsecchi, M.G., Silvestri, D., Campbell, M., Dibar, E., Magyarosy, E., Gadner, H., Stary, J., Benoit, Y., Zimmermann, M., Reiter, A., Riehm, H., Masera, G. & Schrappe, M. Pulses of vincristine and dexamethasone in addition to intensive chemotherapy for children with intermediate-risk acute lymphoblastic leukaemia: a multicentre randomised trial. *Lancet* **369**, 123-131 (2007).
- Attarbaschi, A., Mann, G., Strehl, S., Konig, M., Steiner, M., Jeitler, V., Lion, T., Dworzak, M.N., Gadner, H. & Haas, O.A. Deletion of 11q23 is a highly specific nonrandom secondary genetic abnormality of ETV6 RUNX1-rearranged childhood acute lymphoblastic leukemia. *Leukemia* **21**, 584-586 (2007).
- Stanulla, M. & Schunemann, H.J. Thioguanine versus mercaptopurine in childhood ALL. *Lancet* **368**, 1304-1306 (2006).
- Schrauder, A., Reiter, A., Gadner, H., Niethammer, D., Klingebiel, T., Kremens, B., Peters, C., Ebell, W., Zimmermann, M., Niggli, F., Ludwig, W.D., Riehm, H., Welte, K. & Schrappe, M. Superiority of allogeneic hematopoietic stem-cell transplantation compared with chemotherapy alone in high-risk childhood T-cell acute lymphoblastic leukemia: results from ALL-BFM 90 and 95. *J Clin Oncol* **24**, 5742-5749 (2006).
- Gadner, H., Masera, G., Schrappe, M., Eden, T., Benoit, Y., Harrison, C., Nachman, J. & Pui, C.H. The Eighth International Childhood Acute Lymphoblastic Leukemia Workshop ('Ponte di legno meeting') report: Vienna, Austria, April 27-28, 2005. *Leukemia* **20**, 9-17 (2006).
- Attarbaschi, A., Mann, G., Konig, M., Steiner, M., Strehl, S., Schreiberhuber, A., Schneider, B., Meyer, C., Marschalek, R., Borkhardt, A., Pickl, W.F., Lion, T., Gadner, H., Haas, O.A. & Dworzak, M.N. Mixed lineage leukemia-rearranged childhood pro-B and CD10-negative pre-B acute lymphoblastic leukemia constitute a distinct clinical entity. *Clin Cancer Res* **12**, 2988-2994 (2006).
- Attarbaschi, A., Mann, G., Konig, M., Steiner, M., Dworzak, M.N., Gadner, H. & Haas, O.A. Near-tetraploidy in childhood B-cell precursor acute lymphoblastic leukemia is a highly specific feature of ETV6/RUNX1-positive leukemic cases. *Genes Chromosomes Cancer* **45**, 608-611 (2006).
- Steiner, M., Attarbaschi, A., Konig, M., Nebral, K., Gadner, H., Haas, O.A. & Mann, G. Equal frequency of TEL/AML1 rearrangements in children with acute lymphoblastic leukemia with and without Down syndrome. *Pediatr Hematol Oncol* **22**, 229-234 (2005).

- Steiner, M., Attarbaschi, A., Konig, M., Gadner, H., Haas, O.A. & Mann, G. Equal frequency of TEL/AML1+ acute lymphoblastic leukemia in children with and without Down syndrome. *Pediatr Hematol Oncol* **22**, 11-16 (2005).
- Stanulla, M., Schaffeler, E., Arens, S., Rathmann, A., Schrauder, A., Welte, K., Eichelbaum, M., Zanger, U.M., Schrappe, M. & Schwab, M. GSTP1 and MDR1 genotypes and central nervous system relapse in childhood acute lymphoblastic leukemia. *Int J Hematol* **81**, 39-44 (2005).
- Stanulla, M., Schaeffeler, E., Flohr, T., Cario, G., Schrauder, A., Zimmermann, M., Welte, K., Ludwig, W.D., Bartram, C.R., Zanger, U.M., Eichelbaum, M., Schrappe, M. & Schwab, M. Thiopurine methyltransferase (TPMT) genotype and early treatment response to mercaptopurine in childhood acute lymphoblastic leukemia. *JAMA* **293**, 1485-1489 (2005).
- Peters, C., Schrauder, A., Schrappe, M., von Stackelberg, A., Stary, J., Yaniv, I., Gadner, H. & Klingebiel, T. Allogeneic haematopoietic stem cell transplantation in children with acute lymphoblastic leukaemia: the BFM IBFM/EBMT concepts. *Bone Marrow Transplant* **35 Suppl 1**, S9-11 (2005).
- Moricke, A., Zimmermann, M., Reiter, A., Gadner, H., Odenwald, E., Harbott, J., Ludwig, W.D., Riehm, H. & Schrappe, M. Prognostic impact of age in children and adolescents with acute lymphoblastic leukemia: data from the trials ALL-BFM 86, 90, and 95. *Klin Padiatr* **217**, 310-320 (2005).
- Cloppenburg, T., Stanulla, M., Zimmermann, M., Schrappe, M., Welte, K. & Klein, C. Immunosurveillance of childhood ALL: polymorphic interferon-gamma alleles are associated with age at diagnosis and clinical risk groups. *Leukemia* **19**, 44-48 (2005).
- Cario, G., Stanulla, M., Fine, B.M., Teuffel, O., Neuhoff, N.V., Schrauder, A., Flohr, T., Schafer, B.W., Bartram, C.R., Welte, K., Schlegelberger, B. & Schrappe, M. Distinct gene expression profiles determine molecular treatment response in childhood acute lymphoblastic leukemia. *Blood* **105**, 821-826 (2005).
- Burger, B., Beier, R., Zimmermann, M., Beck, J.D., Reiter, A. & Schrappe, M. Osteonecrosis: a treatment related toxicity in childhood acute lymphoblastic leukemia (ALL)--experiences from trial ALL-BFM 95. *Pediatr Blood Cancer* **44**, 220-225 (2005).
- Balduzzi, A., Valsecchi, M.G., Uderzo, C., De Lorenzo, P., Klingebiel, T., Peters, C., Stary, J., Felice, M.S., Magyarosy, E., Conter, V., Reiter, A., Messina, C., Gadner, H. & Schrappe, M. Chemotherapy versus allogeneic transplantation for very-high-risk childhood acute lymphoblastic leukaemia in first complete remission: comparison by genetic randomisation in an international prospective study. *Lancet* **366**, 635-642 (2005).
- Teuffel, O., Dettling, M., Cario, G., Stanulla, M., Schrappe, M., Buhlmann, P., Niggli, F.K. & Schafer, B.W. Gene expression profiles and risk stratification in childhood acute lymphoblastic leukemia. *Haematologica* **89**, 801-808 (2004).
- Schrappe, M. Evolution of BFM trials for childhood ALL. *Ann Hematol* **83 Suppl 1**, S121-123 (2004).

- Pui, C.H., Schrappe, M., Ribeiro, R.C. & Niemeyer, C.M. Childhood and adolescent lymphoid and myeloid leukemia. *Hematology Am Soc Hematol Educ Program*, 118-145 (2004).
- Pui, C.H., Schrappe, M., Masera, G., Nachman, J., Gadner, H., Eden, O.B., Evans, W.E. & Gaynon, P. Ponte di Legno Working Group: statement on the right of children with leukemia to have full access to essential treatment and report on the Sixth International Childhood Acute Lymphoblastic Leukemia Workshop. *Leukemia* **18**, 1043-1053 (2004).
- Masera, G., Eden, T., Schrappe, M., Nachman, J., Gadner, H., Gaynon, P., Evans, W.E. & Pui, C.H. Statement by members of the Ponte di Legno Group on the right of children to have full access to essential treatment for acute lymphoblastic leukemia. *Pediatr Blood Cancer* **43**, 103-104 (2004).
- Machatschek, J.N., Schrauder, A., Helm, F., Schrappe, M. & Claviez, A. Acute lymphoblastic leukemia and Klinefelter syndrome in children: two cases and review of the literature. *Pediatr Hematol Oncol* **21**, 621-626 (2004).
- Heerema, N.A., Harbott, J., Galimberti, S., Camitta, B.M., Gaynon, P.S., Janka-Schaub, G., Kamps, W., Basso, G., Pui, C.H., Schrappe, M., Auclerc, M.F., Carroll, A.J., Conter, V., Harrison, C.J., Pullen, J., Raimondi, S.C., Richards, S., Riehm, H., Sather, H.N., Shuster, J.J., Silverman, L.B., Valsecchi, M.G. & Arico, M. Secondary cytogenetic aberrations in childhood Philadelphia chromosome positive acute lymphoblastic leukemia are nonrandom and may be associated with outcome. *Leukemia* **18**, 693-702 (2004).
- Bader, P., Kreyenberg, H., Hoelle, W., Dueckers, G., Handgretinger, R., Lang, P., Kremens, B., Dilloo, D., Sykora, K.W., Schrappe, M., Niemeyer, C., Von Stackelberg, A., Gruhn, B., Henze, G., Greil, J., Niethammer, D., Dietz, K., Beck, J.F. & Klingebiel, T. Increasing mixed chimerism is an important prognostic factor for unfavorable outcome in children with acute lymphoblastic leukemia after allogeneic stem-cell transplantation: possible role for pre-emptive immunotherapy? *J Clin Oncol* **22**, 1696-1705 (2004).
- Takeuchi, S., Tsukasaki, K., Bartram, C.R., Seriu, T., Zimmermann, M., Schrappe, M., Takeuchi, N., Park, S., Taguchi, H. & Koeffler, H.P. Long-term study of the clinical significance of loss of heterozygosity in childhood acute lymphoblastic leukemia. *Leukemia* **17**, 149-154 (2003).
- Schrappe, M. Prognostic factors in childhood acute lymphoblastic leukemia. *Indian J Pediatr* **70**, 817-824 (2003).
- Gadner, H., Haas, O.A., Masera, G., Pui, C.H. & Schrappe, M. 'Ponte di Legno' Working Group--report on the Fifth International Childhood Acute Lymphoblastic Leukemia Workshop: Vienna, Austria, 29 April - 1 May 2002. *Leukemia* **17**, 798-803 (2003).
- Burger, B., Zimmermann, M., Mann, G., Kuhl, J., Loning, L., Riehm, H., Reiter, A. & Schrappe, M. Diagnostic cerebrospinal fluid examination in children with acute lymphoblastic leukemia: significance of low leukocyte counts with blasts or traumatic lumbar puncture. *J Clin Oncol* **21**, 184-188 (2003).

- Attarbaschi, A., Mann, G., Kronberger, M., Witt, V., Gadner, H. & Dworzak, M. Effects of dose-reduced Medac L-asparaginase on coagulation in trial ALL-BFM 2000. *Klin Padiatr* **215**, 321-326 (2003).
- Willemse, M.J., Seriu, T., Hettinger, K., d'Aniello, E., Hop, W.C., Panzer-Grumayer, E.R., Biondi, A., Schrappe, M., Kamps, W.A., Maser, G., Gadner, H., Riehm, H., Bartram, C.R. & van Dongen, J.J. Detection of minimal residual disease identifies differences in treatment response between T-ALL and precursor B-ALL. *Blood* **99**, 4386-4393 (2002).
- Schrappe, M., Beier, R. & Burger, B. New treatment strategies in childhood acute lymphoblastic leukaemia. *Best Pract Res Clin Haematol* **15**, 729-740 (2002).
- Pui, C.H., Gaynon, P.S., Boyett, J.M., Chessells, J.M., Baruchel, A., Kamps, W., Silverman, L.B., Biondi, A., Harms, D.O., Vilmer, E., Schrappe, M. & Camitta, B. Outcome of treatment in childhood acute lymphoblastic leukaemia with rearrangements of the 11q23 chromosomal region. *Lancet* **359**, 1909-1915 (2002).
- Muller, H.J., Beier, R., da Palma, J.C., Lanvers, C., Ahlke, E., von Schutz, V., Gunkel, M., Horn, A., Schrappe, M., Henze, G., Kranz, K. & Boos, J. PEG-asparaginase (Oncaspar) 2500 U/m² BSA in reinduction and relapse treatment in the ALL/NHL-BFM protocols. *Cancer Chemother Pharmacol* **49**, 149-154 (2002).
- Langer, T., Martus, P., Ottensmeier, H., Hertzberg, H., Beck, J.D. & Meier, W. CNS late-effects after ALL therapy in childhood. Part III: neuropsychological performance in long-term survivors of childhood ALL: impairments of concentration, attention, and memory. *Med Pediatr Oncol* **38**, 320-328 (2002).
- Dworzak, M.N., Froschl, G., Printz, D., Mann, G., Potschger, U., Muhlegger, N., Fritsch, G. & Gadner, H. Prognostic significance and modalities of flow cytometric minimal residual disease detection in childhood acute lymphoblastic leukemia. *Blood* **99**, 1952-1958 (2002).
- Attarbaschi, A., Mann, G., Dworzak, M., Wiesbauer, P., Schrappe, M. & Gadner, H. Mediastinal mass in childhood T-cell acute lymphoblastic leukemia: significance and therapy response. *Med Pediatr Oncol* **39**, 558-565 (2002).
- Attarbaschi, A., Mann, G., Dworzak, M., Urban, C., Fink, F.M., Dieckmann, K., Riehm, H. & Gadner, H. Treatment results of childhood acute lymphoblastic leukemia in Austria--a report of 20 years' experience. *Wien Klein Wochenschr* **114**, 148-157 (2002).
- zur Stadt, U., Harms, D.O., Schluter, S., Schrappe, M., Goebel, U., Spaar, H., Janka, G. & Kabisch, H. MRD at the end of induction therapy in childhood acute lymphoblastic leukemia: outcome prediction strongly depends on the therapeutic regimen. *Leukemia* **15**, 283-285 (2001).
- Uderzo, C., Balduzzi, A., De Lorenzo, P., Valsecchi, M.G., Gadner, H., Klingebiel, T., Zimmermann, M. & Schrappe, M. Prospective study on allogeneic bone marrow transplantation (allo BMT) versus chemotherapy (chemo) for very high-risk (VHR) childhood acute lymphoblastic leukaemia in first complete remission. *Bone Marrow Transplant* **28 Suppl 1**, S22-24 (2001).

- Muller, H.J., Beier, R., Loning, L., Blutters-Sawatzki, R., Dorffel, W., Maass, E., Muller-Wehrich, S., Scheel-Walter, H.G., Scherer, F., Stahnke, K., Schrappe, M., Horn, A., Lumkemann, K. & Boos, J. Pharmacokinetics of native *Escherichia coli* asparaginase (Asparaginase medac) and hypersensitivity reactions in ALL-BFM 95 reinduction treatment. *Br J Haematol* **114**, 794-799 (2001).
- Lauten, M., Stanulla, M., Zimmermann, M., Welte, K., Riehm, H. & Schrappe, M. Clinical outcome of patients with childhood acute lymphoblastic leukaemia and an initial leukaemic blood blast count of less than 1000 per microliter. *Klin Padiatr* **213**, 169-174 (2001).
- Stanulla, M., Schrappe, M., Brechlin, A.M., Zimmermann, M. & Welte, K. Polymorphisms within glutathione S-transferase genes (GSTM1, GSTT1, GSTP1) and risk of relapse in childhood B-cell precursor acute lymphoblastic leukemia: a case-control study. *Blood* **95**, 1222-1228 (2000).
- Schrappe, M., Reiter, A., Ludwig, W.D., Harbott, J., Zimmermann, M., Hiddemann, W., Niemeyer, C., Henze, G., Feldges, A., Zintl, F., Kornhuber, B., Ritter, J., Welte, K., Gadner, H. & Riehm, H. Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: results of trial ALL-BFM 90. German-Austrian-Swiss ALL-BFM Study Group. *Blood* **95**, 3310-3322 (2000).
- Panzer-Grumayer, E.R., Schneider, M., Panzer, S., Fasching, K. & Gadner, H. Rapid molecular response during early induction chemotherapy predicts a good outcome in childhood acute lymphoblastic leukemia. *Blood* **95**, 790-794 (2000).
- Loning, L., Zimmermann, M., Reiter, A., Kaatsch, P., Henze, G., Riehm, H. & Schrappe, M. Secondary neoplasms subsequent to Berlin-Frankfurt-Munster therapy of acute lymphoblastic leukemia in childhood: significantly lower risk without cranial radiotherapy. *Blood* **95**, 2770-2775 (2000).
- Biondi, A., Valsecchi, M.G., Seriu, T., D'Aniello, E., Willemsse, M.J., Fasching, K., Pannunzio, A., Gadner, H., Schrappe, M., Kamps, W.A., Bartram, C.R., van Dongen, J.J. & Panzer-Grumayer, E.R. Molecular detection of minimal residual disease is a strong predictive factor of relapse in childhood B-lineage acute lymphoblastic leukemia with medium risk features. A case control study of the International BFM study group. *Leukemia* **14**, 1939-1943 (2000).
- Arico, M., Valsecchi, M.G., Camitta, B., Schrappe, M., Chessells, J., Baruchel, A., Gaynon, P., Silverman, L., Janka-Schaub, G., Kamps, W., Pui, C.H. & Masera, G. Outcome of treatment in children with Philadelphia chromosome-positive acute lymphoblastic leukemia. *N Engl J Med* **342**, 998-1006 (2000).
- Wermes, C., Fleischhack, G., Junker, R., Schobess, R., Schwabe, D., Sykora, K.W. & Nowak-Gottl, U. Cerebral venous sinus thrombosis in children with acute lymphoblastic leukemia carrying the MTHFR TT677 genotype and further prothrombotic risk factors. *Klin Padiatr* **211**, 211-214 (1999).
- Sutor, A.H., Mall, V. & Thomas, K.B. Bleeding and thrombosis in children with acute lymphoblastic leukaemia, treated according to the ALL-BFM-90 protocol. *Klin Padiatr* **211**, 201-204 (1999).

- Stanulla, M., Loning, L., Welte, K. & Schrappe, M. Secondary brain tumours in children with ALL. *Lancet* **354**, 1126-1127 (1999).
- Nowak-Gottl, U., Wermes, C., Junker, R., Koch, H.G., Schobess, R., Fleischhack, G., Schwabe, D. & Ehrenforth, S. Prospective evaluation of the thrombotic risk in children with acute lymphoblastic leukemia carrying the MTHFR TT 677 genotype, the prothrombin G20210A variant, and further prothrombotic risk factors. *Blood* **93**, 1595-1599 (1999).
- Dordelmann, M., Reiter, A., Borkhardt, A., Ludwig, W.D., Gotz, N., Viehmann, S., Gadner, H., Riehm, H. & Schrappe, M. Prednisone response is the strongest predictor of treatment outcome in infant acute lymphoblastic leukemia. *Blood* **94**, 1209-1217 (1999).
- van Dongen, J.J., Seriu, T., Panzer-Grumayer, E.R., Biondi, A., Pongers-Willemse, M.J., Corral, L., Stolz, F., Schrappe, M., Masera, G., Kamps, W.A., Gadner, H., van Wering, E.R., Ludwig, W.D., Basso, G., de Bruijn, M.A., Cazzaniga, G., Hettinger, K., van der Does-van den Berg, A., Hop, W.C., Riehm, H. & Bartram, C.R. Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood. *Lancet* **352**, 1731-1738 (1998).
- Schrappe, M., Reiter, A. & Riehm, H. Prophylaxis and treatment of neoplastic meningeosis in childhood acute lymphoblastic leukemia. *J Neurooncol* **38**, 159-165 (1998).
- Schrappe, M., Reiter, A., Henze, G., Niemeyer, C., Bode, U., Kuhl, J., Gadner, H., Havers, W., Pluss, H., Kornhuber, B., Zintl, F., Ritter, J., Urban, C., Niethammer, D. & Riehm, H. Prevention of CNS recurrence in childhood ALL: results with reduced radiotherapy combined with CNS-directed chemotherapy in four consecutive ALL-BFM trials. *Klin Padiatr* **210**, 192-199 (1998).
- Schrappe, M., Arico, M., Harbott, J., Biondi, A., Zimmermann, M., Conter, V., Reiter, A., Valsecchi, M.G., Gadner, H., Basso, G., Bartram, C.R., Lampert, F., Riehm, H. & Masera, G. Philadelphia chromosome-positive (Ph+) childhood acute lymphoblastic leukemia: good initial steroid response allows early prediction of a favorable treatment outcome. *Blood* **92**, 2730-2741 (1998).
- Ratei, R., Sperling, C., Karawajew, L., Schott, G., Schrappe, M., Harbott, J., Riehm, H. & Ludwig, W.D. Immunophenotype and clinical characteristics of CD45-negative and CD45-positive childhood acute lymphoblastic leukemia. *Ann Hematol* **77**, 107-114 (1998).
- Dordelmann, M., Schrappe, M., Reiter, A., Zimmermann, M., Graf, N., Schott, G., Lampert, F., Harbott, J., Niemeyer, C., Ritter, J., Dorffel, W., Nessler, G., Kuhl, J. & Riehm, H. Down's syndrome in childhood acute lymphoblastic leukemia: clinical characteristics and treatment outcome in four consecutive BFM trials. Berlin-Frankfurt-Munster Group. *Leukemia* **12**, 645-651 (1998).
- Dordelmann, M., Reiter, A., Zimmermann, M., Fengler, R., Henze, G., Riehm, H. & Schrappe, M. Intermediate dose methotrexate is as effective as high dose methotrexate in preventing isolated testicular relapse in childhood acute lymphoblastic leukemia. *J Pediatr Hematol Oncol* **20**, 444-450 (1998).

- Welte, K. & Riehm, H. Granulocyte colony-stimulating factor in children with acute lymphoblastic leukemia. *N Engl J Med* **337**, 1320; author reply 1321 (1997).
- Ueberall, M.A., Wenzel, D., Hertzberg, H., Langer, T., Meier, W., Berger-Jones, K., Huk, W.J., Neuhauser, G., Lampert, F., Beck, J.D. & Korinthenberg, R. CNS late effects after ALL therapy in childhood. Part II: Conventional EEG recordings in asymptomatic long-term survivors of childhood ALL--an evaluation of the interferences between neurophysiology, neurology, psychology, and CNS morphology. German Late Effects Working Group. *Med Pediatr Oncol* **29**, 121-131 (1997).
- Ueberall, M.A., Skirl, G., Strassburg, H.M., Wenzel, D., Hertzberg, H., Langer, T., Meier, W., Berger-Jones, K., Huk, W.J., Korinthenberg, R. & Beck, J.D. Neurophysiological findings in long-term survivors of acute lymphoblastic leukaemia in childhood treated with the BFM protocol 81 SR-A B. *Eur J Pediatr* **156**, 727-733 (1997).
- Mielcarek, M., Sperling, C., Schrappe, M., Meyer, U., Riehm, H. & Ludwig, W.D. Expression of intercellular adhesion molecule 1 (ICAM-1) in childhood acute lymphoblastic leukaemia: correlation with clinical features and outcome. *Br J Haematol* **96**, 301-307 (1997).
- Hertzberg, H., Huk, W.J., Ueberall, M.A., Langer, T., Meier, W., Dopfer, R., Skalej, M., Lackner, H., Bode, U., Janssen, G., Zintl, F. & Beck, J.D. CNS late effects after ALL therapy in childhood. Part I: Neuroradiological findings in long-term survivors of childhood ALL--an evaluation of the interferences between morphology and neuropsychological performance. The German Late Effects Working Group. *Med Pediatr Oncol* **28**, 387-400 (1997).
- Conter, V., Schrappe, M., Arico, M., Reiter, A., Rizzari, C., Dordelmann, M., Valsecchi, M.G., Zimmermann, M., Ludwig, W.D., Basso, G., Masera, G. & Riehm, H. Role of cranial radiotherapy for childhood T-cell acute lymphoblastic leukemia with high WBC count and good response to prednisone. Associazione Italiana Ematologia Oncologia Pediatrica and the Berlin-Frankfurt-Munster groups. *J Clin Oncol* **15**, 2786-2791 (1997).
- Borkhardt, A., Cazzaniga, G., Viehmann, S., Valsecchi, M.G., Ludwig, W.D., Burci, L., Mangioni, S., Schrappe, M., Riehm, H., Lampert, F., Basso, G., Masera, G., Harbott, J. & Biondi, A. Incidence and clinical relevance of TEL AML1 fusion genes in children with acute lymphoblastic leukemia enrolled in the German and Italian multicenter therapy trials. Associazione Italiana Ematologia Oncologia Pediatrica and the Berlin-Frankfurt-Munster Study Group. *Blood* **90**, 571-577 (1997).
- Ahlke, E., Nowak-Gottl, U., Schulze-Westhoff, P., Werber, G., Borste, H., Wurthwein, G., Jurgens, H. & Boos, J. Dose reduction of asparaginase under pharmacokinetic and pharmacodynamic control during induction therapy in children with acute lymphoblastic leukaemia. *Br J Haematol* **96**, 675-681 (1997).
- Welte, K., Reiter, A., Mempel, K., Pfetsch, M., Schwab, G., Schrappe, M. & Riehm, H. A randomized phase-III study of the efficacy of granulocyte colony-stimulating factor in children with high-risk acute lymphoblastic leukemia. Berlin-Frankfurt-Munster Study Group. *Blood* **87**, 3143-3150 (1996).

- Schrappe, M., Reiter, A. & Riehm, H. Cytoreduction and prognosis in childhood acute lymphoblastic leukemia. *J Clin Oncol* **14**, 2403-2406 (1996).
- Schlieben, S., Borkhardt, A., Reinisch, I., Ritterbach, J., Janssen, J.W., Ratei, R., Schrappe, M., Repp, R., Zimmermann, M., Kabisch, H., Janka-Schaub, G., Bartram, C.R., Ludwig, W.D., Riehm, H., Lampert, F. & Harbott, J. Incidence and clinical outcome of children with BCR/ABL-positive acute lymphoblastic leukemia (ALL). A prospective RT-PCR study based on 673 patients enrolled in the German pediatric multicenter therapy trials ALL-BFM-90 and CoALL-05-92. *Leukemia* **10**, 957-963 (1996).
- Nowak-Gottl, U., Werber, G., Ziemann, D., Ahlke, E. & Boos, J. Influence of two different *Escherichia coli* asparaginase preparations on fibrinolytic proteins in childhood ALL. *Haematologica* **81**, 127-131 (1996).
- Boos, J., Werber, G., Ahlke, E., Schulze-Westhoff, P., Nowak-Gottl, U., Wurthwein, G., Verspohl, E.J., Ritter, J. & Jurgens, H. Monitoring of asparaginase activity and asparagine levels in children on different asparaginase preparations. *Eur J Cancer* **32A**, 1544-1550 (1996).
- Nowak-Gottl, U., Rath, B., Binder, M., Hassel, J.U., Wolff, J., Husemann, S. & Ritter, J. Inefficacy of fresh frozen plasma in the treatment of L-asparaginase-induced coagulation factor deficiencies during ALL induction therapy. *Haematologica* **80**, 451-453 (1995).
- Schrappe, M., Reiter, A., Sauter, S., Ludwig, W.D., Wormann, B., Harbott, J., Bender-Gotze, C., Dorffel, W., Dopfer, R., Frey, E. & et al. [Concept and interim result of the ALL-BFM 90 therapy study in treatment of acute lymphoblastic leukemia in children and adolescents: the significance of initial therapy response in blood and bone marrow]. *Klin Padiatr* **206**, 208-221 (1994).
- Reiter, A., Schrappe, M., Ludwig, W.D., Hiddemann, W., Sauter, S., Henze, G., Zimmermann, M., Lampert, F., Havers, W., Niethammer, D. & et al. Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients. Results and conclusions of the multicenter trial ALL-BFM 86. *Blood* **84**, 3122-3133 (1994).
- Izraeli, S., Janssen, J.W., Haas, O.A., Harbott, J., Brok-Simoni, F., Walther, J.U., Kovar, H., Henn, T., Ludwig, W.D., Reiter, A. & et al. Detection and clinical relevance of genetic abnormalities in pediatric acute lymphoblastic leukemia: a comparison between cytogenetic and polymerase chain reaction analyses. *Leukemia* **7**, 671-678 (1993).
- Hiddemann, W., Harbott, J., Ludwig, W.D., Ritter, J., Nehmer, A., Reiter, A., Kolkmeier, A., Laing, T. & Riehm, H. DNA aneuploidy in childhood acute lymphoblastic leukemia: relation to clinical determinants and prognosis within four consecutive BFM trials. *Recent Results Cancer Res* **131**, 113-121 (1993).
- Harbott, J., Ritterbach, J., Ludwig, W.D., Bartram, C.R., Reiter, A. & Lampert, F. Clinical significance of cytogenetic studies in childhood acute lymphoblastic leukemia: experience of the BFM trials. *Recent Results Cancer Res* **131**, 123-132 (1993).

- van der Does-van den Berg, A., Bartram, C.R., Basso, G., Benoit, Y.C., Biondi, A., Debatin, K.M., Haas, O.A., Harbott, J., Kamps, W.A., Koller, U. & et al. Minimal requirements for the diagnosis, classification, and evaluation of the treatment of childhood acute lymphoblastic leukemia (ALL) in the "BFM Family" Cooperative Group. *Med Pediatr Oncol* **20**, 497-505 (1992).
- Sutor, A.H., Niemeyer, C., Sauter, S., Witt, I., Kaufmehl, K., Rombach, A., Brandis, M. & Riehm, H. [Changes in blood coagulation in treatment with ALL-BFM-90 and NHL-BFM-90 protocols]. *Klin Padiatr* **204**, 264-273 (1992).
- Reiter, A., Schrappe, M., Ludwig, W.D., Lampert, F., Harbott, J., Henze, G., Niemeyer, C.M., Gadner, H., Muller-Wehrich, S., Ritter, J. & et al. Favorable outcome of B-cell acute lymphoblastic leukemia in childhood: a report of three consecutive studies of the BFM group. *Blood* **80**, 2471-2478 (1992).
- Ritter, J., Creutzig, U., Reiter, A., Riehm, H. & Schellong, G. Childhood leukemia: cooperative Berlin-Frankfurt-Munster trials in the Federal Republic of Germany. *J Cancer Res Clin Oncol* **116**, 100-103 (1990).
- Riehm, H., Gadner, H., Henze, G., Kornhuber, B., Lampert, F., Niethammer, D., Reiter, A. & Schellong, G. Results and significance of six randomized trials in four consecutive ALL-BFM studies. *Haematol Blood Transfus* **33**, 439-450 (1990).
- Riehm, H., Gadner, H., Henze, G., Kornhuber, B., Lampert, F., Niethammer, D., Reiter, A. & Schellong, G. Results and significance of six randomized trials in four consecutive ALL-BFM studies. *Haematol Blood Transfus* **33**, 439-450 (1990).
- Ludwig, W.D., Teichmann, J.V., Sperling, C., Komischke, B., Ritter, J., Reiter, A., Odenwald, E., Sauter, S. & Riehm, H. [Incidence, clinical markers and prognostic significance of immunologic subtypes of acute lymphoblastic leukemia (ALL) in children: experiences of the ALL-BFM 83 and 86 studies]. *Klin Padiatr* **202**, 243-252 (1990).
- Buhner, C., Henze, G., Hofmann, J., Reiter, A., Schellong, G. & Riehm, H. Central nervous system relapse prevention in 1165 standard-risk children with acute lymphoblastic leukemia in five BFM trials. *Haematol Blood Transfus* **33**, 500-503 (1990).
- Ludwig, W.D., Seibt-Jung, H., Teichmann, J.V., Komischke, B., Gatzke, A., Gassner, G., Odenwald, E., Hofmann, J. & Riehm, H. Clinicopathological features and prognostic implications of immunophenotypic subgroups in childhood ALL: experience of the BFM-ALL Study 83. *Haematol Blood Transfus* **32**, 51-57 (1989).
- Bucsky, P., Reiter, A., Ritter, J., Dopfer, R. & Riehm, H. [Acute lymphoblastic leukemia in infancy: results of 5 multicenter ALL-BFM therapy studies 1970-1986]. *Klin Padiatr* **200**, 177-183 (1988).
- Schrappe, M., Beck, J., Brandeis, W.E., Feickert, H.J., Gadner, H., Graf, N., Havers, W., Henze, G., Jobke, A., Kornhuber, B. & et al. [Treatment of acute lymphoblastic leukemia in childhood and adolescence: results of the multicenter therapy study ALL-BFM 81]. *Klin Padiatr* **199**, 133-150 (1987).
- Riehm, H., Reiter, A., Schrappe, M., Berthold, F., Dopfer, R., Gerein, V., Ludwig, R., Ritter, J., Stollmann, B. & Henze, G. [Corticosteroid-dependent

reduction of leukocyte count in blood as a prognostic factor in acute lymphoblastic leukemia in childhood (therapy study ALL-BFM 83)]. *Klin Padiatr* **199**, 151-160 (1987).

- Riehm, H., Feickert, H.J., Schrappe, M., Henze, G. & Schellong, G. Therapy results in five ALL-BFM studies since 1970: implications of risk factors for prognosis. *Haematol Blood Transfus* **30**, 139-146 (1987).
- Riehm, H. [Appraisal of the status of pediatric oncology in West Germany]. *Klin Padiatr* **199**, 131-132 (1987).
- Hiddemann, W., Wormann, B., Ritter, J., Thiel, E., Gohde, W., Lahme, B., Henze, G., Schellong, G., Riehm, H. & Buchner, T. Frequency and clinical significance of DNA aneuploidy in acute leukemia. *Ann N Y Acad Sci* **468**, 227-240 (1986).
- Riehm, H. Pediatric oncology in Hannover, West Germany. *Am J Pediatr Hematol Oncol* **7**, 396 (1985).
- Lampert, F., Henze, G., Langermann, H.J., Schellong, G., Gadner, H. & Riehm, H.J. Acute lymphoblastic leukemia: current status of therapy in children. *Recent Results Cancer Res* **93**, 159-181 (1984).
- Henze, G., Langermann, H.J., Bramswig, J., Schellong, G., Ludwig, R. & Riehm, H. [Results of preventive management of the central nervous system in 275 children with acute lymphoblastic leukemia]. *Klin Padiatr* **195**, 168-175 (1983).
- Langermann, H.J., Henze, G., Wulf, M. & Riehm, H. [Estimation of tumor cell mass in childhood acute lymphoblastic leukemia: prognostic significance and practical application]. *Klin Padiatr* **194**, 209-213 (1982).
- Henze, G., Langermann, H.J., Fengler, R., Brandeis, M., Evers, K.G., Gadner, H., Hinderfeld, L., Jobke, A., Kornhuber, B., Lampert, F., Lasson, U., Ludwig, R., Muller-Wehrich, S., Neidhardt, M., Nessler, G., Niethammer, D., Rister, M., Ritter, J., Schaaff, A., Schellong, G., Stollmann, B., Treuner, J., Wahlen, W., Weinel, P., Wehinger, H. & Riehm, H. [Acute lymphoblastic leukemia therapy study BFM 79/81 in children and adolescents: intensified reinduction therapy for patients with different risk for relapse]. *Klin Padiatr* **194**, 195-203 (1982).
- Henze, G., Langermann, H.J., Ritter, J., Schellong, G. & Riehm, H. Treatment strategy for different risk groups in childhood acute lymphoblastic leukemia: A Report From the BFM Study Group. *Haematol Blood Transfus* **26**, 87-93 (1981).
- Henze, G., Langermann, H.J., Kaufmann, U., Ludwig, R., Schellong, G., Stollmann, B. & Riehm, H. Thymic involvement and initial white blood count in childhood acute lymphoblastic leukemia. *Am J Pediatr Hematol Oncol* **3**, 369-376 (1981).
- Henze, G., Langermann, H.J., Bramswig, J., Breu, H., Gadner, H., Schellong, G., Welte, K. & Riehm, H. [The BFM 76/79 acute lymphoblastic leukemia therapy study (author's transl)]. *Klin Padiatr* **193**, 145-154 (1981).

- Riehm, H., Gardner, H., Henze, G., Langermann, H.J. & Odenwald, E. The Berlin Childhood Acute Lymphoblastic Leukemia Therapy Study, 1970-1976. *Amer J Ped Hem/Onc* **2**, 299-305 (1980).
- Riehm, H., Gardner, H. & Welte, K. [The west-berlin therapy study of acute lymphoblastic leukemia in childhood--report after 6 years (author's transl)]. *Klin Padiatr* **189**, 89-102 (1977).